ArticleAtherosclerosis plus2026
Associations of long-term vitamin K antagonist and direct oral anticoagulant therapies with progression of coronary artery calcification: A Danish population-based study.
Article in Atherosclerosis plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Vitamin K antagonists (VKAs) may promote vascular calcification through inhibition of vitamin K-dependent proteins. We aimed to examine the association between long-term anticoagulant therapy with VKA or direct oral anticoagulants (DOACs) and progression of coronary artery calcification (CAC) in a large, population-based cohort. Methods: We included men and women (<75 years) with two non-contrast CT scans for CAC ≥4 years apart, categorized into VKA, DOAC, mixed anticoagulant, and control groups. Cumulative treatment duration was calculated from prescription data. CAC progression was analysed using zero-inflated negative binomial and multinomial logistic regression, adjusting for traditional cardiovascular risk factors, baseline CAC and follow-up time. Sensitivity analyses excluded participants predisposed to vascular mineralization (statin use, mechanical valve, renal impairment). Results: 7365 participants with similar risk profile were included. VKA therapy was significantly associated with CAC progression (incidence rate ratio (IRR) = 1.004 per month of treatment (95% CI: 1.000-1.007)), showing a duration-response relationship. Long-term VKA therapy (>48months) was independently associated with higher CAC progression (IRR = 1.43 (95% CI: 1.076-1.908)), and an increased risk of having severe CAC (CAC score ≥400) at follow-up (relative risk ratio (RRR) = 1.012 per month of treatment (95% CI: 1.001-1.023)). In contrast, DOAC therapy was not associated with CAC progression. Sensitivity analyses confirmed that the association with VKA was not driven by high-risk subgroups. Conclusion: In this large, real-world cohort, VKA - but not DOAC - therapy was associated with accelerated, duration-dependent CAC progression. These findings suggest that choice of anticoagulant may influence CAC, yet the clinical implications remain to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.